Samsung Biologics (207940) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Samsung Biologics (207940) reported revenue of 4.56 trillion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20254.56 trillion KRW2.07 trillion KRW1.78 trillion KRW[source]
20244.55 trillion KRW1.32 trillion KRW1.08 trillion KRW[source]
20233.69 trillion KRW1.11 trillion KRW857.7 billion KRW[source]
20223.00 trillion KRW983.6 billion KRW798.1 billion KRW[source]
20211.57 trillion KRW537.3 billion KRW393.6 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202511.02 trillion KRW3.61 trillion KRW7.42 trillion KRW[source]
202413.32 trillion KRW4.04 trillion KRW9.28 trillion KRW[source]
202311.83 trillion KRW3.59 trillion KRW8.24 trillion KRW[source]
202212.17 trillion KRW4.87 trillion KRW7.30 trillion KRW[source]
20215.90 trillion KRW2.49 trillion KRW3.42 trillion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice